Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Reform in 2013: The Sprint to the Starting Line

This article was originally published in RPM Report

Executive Summary

The Affordable Care Act has nearly died at least three times since the final bill took shape in 2010; with the re-election of Barack Obama, it is all systems go. But remember, the race to implement the program by 2014 is only the beginning, not the end, of health care reform.

You may also be interested in...



Medicaid Expansion: Glass Half Full for Biopharma

Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.

Hedge Fund Offers Policy Prescriptions

“Status Quo” Election Means Stability in Administration Overseeing Rapid Change in Policy Climate

The re-election of Barack Obama injects some stability into a period of rapid change in regulatory and health policy. Most key health officials are expected to stay at least until 2014, and that is likely to include FDA Commissioner Margaret Hamburg. But there are plenty of big changes in key slots on Capitol Hill, and the implementation of health reform and PDUFA V will mean a lot is new even if the political lineups aren’t.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel